Aromatase inhibitors (AIs) are becoming the hormonal treatment of choice for postmenopausal women with early breast cancer. Large, well-controlled clinical studies have established the efficacy ...

Seth Wander, MD, PhD, discusses the tolerability of selective estrogen receptor degraders and next-generation anti-estrogen ...

Early initiation of moderate-intensity aerobic exercise reduced pain compared with standard care among postmenopausal women who received aromatase inhibitors.

In the case of breast cancer, women with a higher BMI do have higher rates of recurrence compared to women in the "normal" ...

Studying the possible association between AI and cognitive dysfunction has accelerated over the past 7 years. A pilot study using neuropsychological testing from the Arimidex, Tamoxifen, Alone or ...

Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according ...

C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment.

AstraZeneca has reported positive outcomes from a planned interim analysis of the double-blind Phase III SERENA-6 trial of ...

As VERZENIO gains traction in early-stage treatments and broadens its approved uses, its revenue is expected to keep growing. While the global CDK4/6 inhibitor market remains highly competitive ...